Clinical Studies for ES-SCLC
Exploring a potential new approach for extensive-stage small-cell lung cancer.
Take the survey About the trial:
These studies are evaluating an investigational immunotherapy drug in patients with extensive-stage small-cell lung cancer (ES-SCLC). The goal is to determine whether adding this drug can safely improve cancer control and survival in ES-SCLC.
Even with current therapies, people with ES-SCLC typically have a median survival of 7 to 11 months.1
Because many SCLC cases do not respond long-term to chemotherapy alone, adding potential new therapies could help engage the immune system to fight back.2
Take the surveyYou might be eligible if you:
Are over 18 years old
Have been diagnosed with ES-SCLC
Are considering your treatment options
Are interested in participating in a clinical trial
Take a quick survey today to see if you prequalify.
Take the surveyTake the Survey
Find out if you prequalify instantly.